Dopamine Agonist 3-PPP Fails to Protect Against MPTP-Induced Toxicity

Neurochemical Research

Volumn 29, Issue 2, 2004, Pages 379-384

  Muralikrishnan, Dhanasekaran ^a   Ebadi, Manuchair ^a   Brown Borg, Holly M ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

3 PPP Hydrochloride; Dopamine uptake; Monoamine oxidase B activity; MPTP; Neuroprotection

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; PRECLAMOL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; ENZYME ACTIVITY; MOUSE; NERVE CELL CULTURE; NERVE CELL GROWTH; NEUROPHARMACOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BEHAVIOR, ANIMAL; CELL DIVISION; CELL LINE, TUMOR; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; HUMANS; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE; MPTP POISONING; NEUROPROTECTIVE AGENTS; PIPERIDINES; TREATMENT FAILURE;

ANIMALIA; GYMNOMYZA SAMOENSIS;

EID: 1242336749     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NERE.0000013740.53483.39     Document Type: Article

References (45)

1. Arai, N., Isaji, M., Miyata, H., Fukuyama, J., Mizuta, E., and Kuno, S. Differential effects of three dopamine receptor agonists in MPTP-treated monkeys. 1995. J. Neural Transm. 10:55-62.
2. Piercey, M. F. 1998. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin. Neuropharmacol. 21:141-151.
3. Pirtosek, Z., Merello, M., Carlsson, A., and Stern, G. 1993. Preclamol and parkinsonian fluctuations. Clin. Neuropharmacol. 16:550-554.
4. Pirtosek, Z., Merello, M., Carlsson, A., and Stern, G. 1996. Preclamol. A "designer drug" in the treatment of advanced Parkinson's disease. Adv. Neurol. 69:535-540.
5. Barone, P., Bravi, D., Bermejo-Pareja, F., Marconi, R., Kulisevsky, J., Malagu, S., Weiser, R., and Rost, N. 1999. Pergolide monotherapy in the treatment of early PD: A randomized, controlled study-Pergolide Monotherapy Study Group. Neurology 53:573-579.
6. Calne, D. B., Teychenne, P. F., Claveria, L. E., Eastman, R., Greenacre, J. K., and Petne, A. 1974. Bromocriptine in parkinsonism. Br. Med. J. 4:442-444.
7. Hayashi, R., Tako, K., Makishita, H., Koyama, J., and Yanagisawa N. 1998. Efficacy of a low-dose subcutaneous lisuride infusion in Parkinson's disease. Intern. Med. 37:444-448.
8. Jeret, J. S. 1999. A multicenter trial of ropinirole as adjunct treatment for PD. Neurology 53:658.
9. Langston, J. W., Ballard, P., Tetrud, J. W., and Irwin, I. 1983. Chronic parkinsonism in humans due to a product of mepiridine-analog synthesis. Science 219:979-980.
10. Blanchet, P., Bedard, P. J., Britton, D. R., and Kebabian, J. W. 1993. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J. Pharmacol. Exp. Ther. 267:275-279.
11. Heikkila, R. E., Hess, A., and Duvoisin, R. C. 1984. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224:1451-1453.
12. Heikkila, R. E., Cabbat, F. S., Manzino, L., and Duvoisin, R. C. 1984. Effects of 1-methyl-4-phenyl 1,2,5,6-tetrahydropyridine on neostriatial dopamine in mice. Neuropharmacology 23:711-713.
13. Chiba, K. A., Trevor, N., and Castognoli Jr. 1984. Metabolism of the neurotoxic tertiary amine by monoamine oxidase. Biochem. Biophys. Res. Commun. 120:574-578.
14. Heikkila, R. E., Manzino, L., Cabbat, F. S., and Duvoisin, R. C. 1984. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467-469.
15. Robinson, D. S. 1975. Changes in monoamine oxidase and monoamines with human development and aging. Fed. Proc. 34:103-107.
16. Mitra, N., Mohanakumar, K. P., and Ganguly, D. K. 1994. Resistance of golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine: Relationship with low levels of regional monoamine oxidase-B. J. Neurochem. 62:1906-1912.
17. + by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin. Eur. J. Pharmacol. 106:455-456.
18. Mizuno, Y., Suzuki, K., Sone, N., and Saitoh, T. 1988. Inhibition of mitochondrial respiration by 1-methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine (MPTP) in mouse brain in vivo. Neurosci. Lett. 91:349-353.
19. Thomas, B., Muralikrishnan, D., and Mohanakumar, K. P. 2000. In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res. 85:221-224.
20. Mohanakumar, K. P., Muralikrishnan, D., and Thomas, B. 2000 Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Res. 12:281-290.
21. Storch, A., Burkhardt, K., Ludolph, A. C., and Schwarz, J. 2000. Protective effects of riluzole on dopamine neurons: Involvement of oxidative stress and cellular energy metabolism. J. Neurochem. 75:2259-2269.
22. Mohanakumar K. P. and Sood P. P. 1985. Behavioural and chemical changes in mice during morphine dependence development, withdrawal and naloxone administration. Cell Mol. Biol. 31:463-468.
23. Weihmuller, F. B., Hadjiconstantinou, M., and Bruno, J. P. 1988. Acute stress or neuroleptics elicit sensorimotor deficits in MPTP-treated mice. Neurosci. Lett. 85:137-142.
24. Muralikrishnan, D., Ebadi, M., and Brown-Borg H. 2002. Effect of MPTP on dopamine metabolism in Ames dwarf mice. Neurochem. Res. 27:457-464.
25. Muralikrishnan, D. and Ebadi, M. 2001. SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine-induced neurotoxicity. Brain Res. 892:241-248.
26. Morinan, A. and Garratt, H. M. 1985. An improved fluorimetric assay for brain monoamine oxidase. J. Pharmacol. Methods 13:213-223.
27. Mohanakumar, K. P., Mohanty, S., and Ganguly, D. K. 1995. Neonatal treatment with 5-HT antiserum alters 5-HT metabolism and function in adult rats. Neuroreport 7:238-240.
28. Wagle, A. and Singh, J. P. 2000. Fibroblast growth factor protects nitric oxide-induced apoptosis in neuronal SH-SY5Y cells. J. Pharmacol. Exp. Ther. 295:889-895.
29. Drukarch, B., Jongenelen, C. A. M., Schepens, E., Langeveld, C. H., and Stoof, J. C. 1996. Glutathione is involved in the granular storage of dopamine in rat PC12 pheochrocytoma cells: Implications for the pathogenesis of parkinson disease. J. Neurosci. 16:6038-6045.
30. Muralikrishnan, D. and Mohanakumar, K. P. 1998. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine-induced neurotoxicity in mice. FASEB J. 12:905-912.
31. +), the toxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicology 49:17-23.
32. Royland, J. E., Delfani, K., Langston, J. W., Janson, A. M., and Di Monte, D. A. 1999. 7-Nitroindazole prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced ATP loss in the mouse striatum. Brain Res. 839:41-48.
33. Yu, P. H., Davis, B. A., Durden, D. A., Barber, A., Terleckyj, I., Nicklas, W. G., and Boulton, A. A. 1994. Neurochemical and neuroprotective effects of some aliphatic propargylamines: New selective nonamphetamine-like monoamine oxidase B inhibitors. J. Neurochem. 62:697-704.
34. Schultz, W., Scarnati, E., Sundstrom, E., Tsutsumi T., and Jonsson G. 1986. The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys. Exp. Brain. Res. 63:216-220.
35. Javitch, J. A., D'Amato, R. J., Strittmatter, S. M., and Snyder, S. H. 1985. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA 82:2173-2177.
36. Metman, I. V., Sethy, V. H., Roberts, J. R., Bravi, D., Hoff, J. I., Mouradian, M. M., and Chase, T. N. 1994. Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease. Mov. Disord. 95:77-81.
37. Peacock, L. and Gerlach, J. 1993. Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol. Eur. J. Pharmacol. 237:329-340.
38. Lahti, A. C., Weiler, M. A., Corey, P. K., Lahti, R. A., Carlsson, A., and Tamminga, C. A. 1998. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia. Biol. Psychiatry 43:2-11.
39. Clow, A., Hussain, T., Glover, V., Sandler, M., Walker, M., and Dexter, D. 1992. Pergolide can induce soluble superoxide dismutase in rat striata. J. Neural. Transm. Gen. Sect. 90:27-31.
40. Clow, A., Freestone, C., Lewis, E., Dexter, D., Sandler, M., and Glover, V. 1993. The effect of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase. Neurosci Lett. 24:41-43.
41. Glover, V., Clow, A., and Sandler, M. 1993. Effects of dopaminergic drugs on superoxide dismutase: Implications for senescence. J. Neural. Transm. Suppl. 40:37-45.
42. Thiffault, C., Aumont, N., Quinon, R., and Poirier, J. 1995. Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. J. Neurochem. 65:2725-2733.
43. Liu, X. H., Kato, H., Chen, T., Kato, K., and Itoyama, Y. 1995. Bromocriptine protects against delayed neuronal death of hippocampal neurons following cerebral ischemia in the gerbil. J. Neurol. Sci. 129:9-14.
44. Spina, M. B., Squinto, S. P., Miller, J., Lindsay, R. M., and Hyman, C. 1993. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpylidinium ion toxicity: Involvement of the glutathione system. J. Neurochem. 60:1582-1583.
45. Kitamura, Y., Kosaka, T., Kakimura, J. I., Matsuoka, Y., Kohno, Y., Nomura, Y., and Taniguchi, T. 1998. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 54:1046-1054.